Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial
    Meeting Abstract

    Suehara, Y.; Arcila, M. E.; Drilon, A. E. D.; Ito, T.; Wang, L.; Hasanovic, A.; Khanin, R.; Rizvi, N. A.; Ladanyi, M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    Meeting Abstract

    Natale, R. B.; Rizvi, N. A.; Infante, J. R.; Joseph, L. J.; Viner, J.; McDevitt, J. T.; Ji, F.; Shin, S.; Liang, M.; Burris, H. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer
    Meeting Abstract

    Gettinger, S. N.; Rizvi, N. A.; Shepherd, F. A.; Chow, L. Q.; Laurie, S. A.; Spigel, D. R.; Sbar, E.; Shen, Y.; Brahmer, J. R.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers
    Meeting Abstract

    Chaft, J. E.; Paik, P. K.; Sima, C. S.; Kris, M. G.; Krug, L. M.; Azzoli, C. G.; Riely, G. J.; Pietanza, M. C.; Rusch, V. W.; Travis, W. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
    Journal Article

    Suehara, Y.; Arcila, M.; Wang, L.; Hasanovic, A.; Ang, D.; Ito, T.; Kimura, Y.; Drilon, A.; Guha, U.; Rusch, V.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    Journal Article

    Pietanza, M. C.; Gadgeel, S. M.; Dowlati, A.; Lynch, T. J.; Salgia, R.; Rowland, K. M. Jr; Wertheim, M. S.; Price, K. A.; Riely, G. J.; Azzoli, C. G.; more...
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    Journal Article

    Pietanza, M. C.; Kadota, K.; Huberman, K.; Sima, C. S.; Fiore, J. J.; Sumner, D. K.; Travis, W. D.; Heguy, A.; Ginsberg, M. S.; Holodny, A. I.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib
    Journal Article

    Chmielecki, J.; Pietanza, M. C.; Aftab, D.; Shen, R.; Zhao, Z.; Chen, X.; Hutchinson, K.; Viale, A.; Kris, M. G.; Stout, T.; more...
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save